Skip to main content
    P

    Pfizer Inc (PFE)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $28.88
    -0.01 (-0.03%)

    Market Cap: $164.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pfizer Inc (PFE) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Pfizer (PFE) to earn $3.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $63.13B. Of 28 analysts, 9 rate the stock Buy or Strong Buy, 17 Hold and 2 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $2.95.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 32% of the ratings.

    RatingAnalystsShare
    Strong Buy13.6%
    Buy828.6%
    Hold1760.7%
    Sell13.6%
    Strong Sell13.6%
    Consensus
    Hold
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 3.3% and revenue estimates fall 3.7%.

    Fiscal year ending Dec 31, 2026
    $3.05
    EPS consensus, revenue $63.13B
    Fiscal year ending Dec 31, 2027
    $2.95
    EPS consensus, revenue $60.82B
    Next report
    Feb 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.05$2.90 to $3.2223$63.13B$61.33B to $63.97B25
    Dec 31, 2027$2.95$2.54 to $3.1824$60.82B$58.68B to $63.10B25

    Quarterly Estimates

    The EPS consensus rises from $0.69 for the quarter ending Dec 31, 2026 to $0.70 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.69$0.62 to $0.8720$17.37B$16.25B to $18.80B18
    Mar 31, 2027$0.70$0.56 to $0.778$14.12B$13.80B to $14.43B7

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2027154

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.3% from $2.98.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.05$3.04$2.96$2.98$2.98+2.5%
    Fiscal year ending Dec 31, 2027$2.95$2.94$2.89$2.90$2.90+1.8%
    Quarter ending Mar 31, 2027$0.70$0.70$0.68$0.67$0.67+4.1%

    Frequently Asked Questions About PFE

    What is the PFE stock forecast?

    Consensus analyst estimates put Pfizer's EPS at $3.05 for the fiscal year ending Dec 31, 2026, on revenue of $63.13B. The consensus rating from 28 analysts is Hold.

    How do analysts rate PFE stock?

    Of 28 analysts covering Pfizer, 1 rates it Strong Buy, 8 Buy, 17 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from PFE next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.05, with estimates from $2.90 to $3.22 from 23 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.95, with estimates from $2.54 to $3.18 from 24 analysts.

    What revenue do analysts expect from Pfizer next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $63.13B, with estimates from $61.33B to $63.97B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $60.82B, with estimates from $58.68B to $63.10B.

    How many analysts cover PFE?

    28 analysts rate Pfizer stock, and 23 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.